News
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback